Subscribe
ftc
parbradyphoto / iStockphoto.com
19 December 2018Big Pharma

FTC agrees to re-open Actavis and Watson merger decision

The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva settles Sensipar patent dispute with Amgen
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
Teva and FTC reach settlement over ‘pay-for-delay’
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
Americas
FTC launches pharma merger analysis group
18 March 2021   The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Teva settles Sensipar patent dispute with Amgen
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
Teva and FTC reach settlement over ‘pay-for-delay’
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
Americas
FTC launches pharma merger analysis group
18 March 2021   The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.

More on this story

Big Pharma
Teva settles Sensipar patent dispute with Amgen
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
Teva and FTC reach settlement over ‘pay-for-delay’
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
Americas
FTC launches pharma merger analysis group
18 March 2021   The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent